Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium

Journal of the American College of Cardiology

Volumn 71, Issue 20, 2018, Pages 2360-2372

  Packer, Milton ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

epicardial adipose tissue; heart failure; obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALDOSTERONE; ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MEMBRANE METALLOENDOPEPTIDASE; MINERALOCORTICOID ANTAGONIST; NATRIURETIC FACTOR; RESISTIN; TUMOR NECROSIS FACTOR; AUTACOID;

ADIPOCYTE; ADIPOGENESIS; BODY MASS; BODY WEIGHT GAIN; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TARGETING; DYSLIPIDEMIA; ENZYME INHIBITION; EPICARDIAL FAT; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART STRESS; HEART VENTRICLE REMODELING; HIGH RISK PATIENT; INTRA-ABDOMINAL FAT; MYOCARDITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; ADIPOSE TISSUE; CARDIAC MUSCLE; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY; PERICARDIUM; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADIPOSE TISSUE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTRA-ABDOMINAL FAT; MYOCARDIUM; OBESITY; PERICARDIUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85050821660     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.03.509     Document Type: Review

References (228)

1. Kenchaiah, S., Evans, J.C., Levy, D., et al. Obesity and the risk of heart failure. N Engl J Med 347 (2002), 305–313.
2. Sundström, J., Bruze, G., Ottosson, J., Marcus, C., Näslund, I., Neovius, M., Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment. Circulation 135 (2017), 1577–1585.
3. Persson, C.E., Björck, L., Lagergren, J., Lappas, G., Giang, K.W., Rosengren, A., Risk of heart failure in obese patients with and without bariatric surgery in Sweden-a registry-based study. J Card Fail 23 (2017), 530–537.
4. Packer, M., Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation 137 (2018), 1614–1631.
5. Dornfeld, L.P., Maxwell, M.H., Waks, A., Tuck, M., Mechanisms of hypertension in obesity. Kidney Int Suppl 22 (1987), S254–S258.
6. Reddy, Y.N., Melenovsky, V., Redfield, M.M., Nishimura, R.A., Borlaug, B.A., High-output heart failure: a 15-year experience. J Am Coll Cardiol 68 (2016), 473–482.
7. Obokata, M., Reddy, Y.N.V., Pislaru, S.V., Melenovsky, V., Borlaug, B.A., Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 136 (2017), 6–19.
8. Kitzman, D.W., Shah, S.J., The HFpEF obesity phenotype: the elephant in the room. J Am Coll Cardiol 68 (2016), 200–203.
9. Mahajan, R., Lau, D.H., Sanders, P., Impact of obesity on cardiac metabolism, fibrosis, and function. Trends Cardiovasc Med 25 (2015), 119–126.
10. Cavalera, M., Wang, J., Frangogiannis, N.G., Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res 164 (2014), 323–335.
11. Mohammed, S.F., Hussain, S., Mirzoyev, S.A., Edwards, W.D., Maleszewski, J.J., Redfield, M.M., Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131 (2015), 550–559.
12. Rommel, K.P., von Roeder, M., Latuscynski, K., et al. Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 67 (2016), 1815–1825.
13. Su, M.Y., Lin, L.Y., Tseng, Y.H., et al. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. J Am Coll Cardiol Img 7 (2014), 991–997.
14. Duca, F., Kammerlander, A.A., Zotter-Tufaro, C., et al. Interstitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction: insights from a prospective cardiac magnetic resonance imaging study. Circ Cardiovasc Imaging, 9, 2016, e005277.
15. Ghigliotti, G., Barisione, C., Garibaldi, S., et al. Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. Inflammation 37 (2014), 1337–1353.
16. Berg, A.H., Scherer, P.E., Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96 (2005), 939–949.
17. Levitsky, A., Brismar, K., Hafström, I., et al. Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. RMD Open, 3, 2017, e000458.
18. Lake, J.E., The fat of the matter: obesity and visceral adiposity in treated HIV infection. Curr HIV/AIDS Rep 14 (2017), 211–219.
19. Maglio, C., Peltonen, M., Rudin, A., Carlsson, L.M.S., Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish Obese Subjects Study. Obesity (Silver Spring) 25 (2017), 2068–2073.
20. Schieir, O., Tosevski, C., Glazier, R.H., Hogg-Johnson, S., Badley, E.M., Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann Rheum Dis 76 (2017), 1396–1404.
21. Freiberg, M.S., Chang, C.C., Kuller, L.H., et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 173 (2013), 614–622.
22. Fernández-Gutiérrez, B., Perrotti, P.P., Gisbert, J.P., et al. Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts. Medicine (Baltimore), 96, 2017, e7308.
23. Nakamura, Y., Takemori, H., Shiraishi, K., et al. Compensatory enlargement of angiographically normal coronary segments in patients with coronary artery disease. In vivo documentation using intravascular ultrasound. Angiology 47 (1996), 775–781.
24. Aranda, J.M. Jr., Hill, J., Cardiac transplant vasculopathy. Chest 118 (2000), 1792–1800.
25. Lima-Martínez, M.M., Campo, E., Salazar, J., et al. Epicardial fat thickness as cardiovascular risk factor and therapeutic target in patients with rheumatoid arthritis treated with biological and nonbiological therapies. Arthritis, 2014, 2014, 782850.
26. Wang, X., Guo, Z., Zhu, Z., Bao, Y., Yang, B., Epicardial fat tissue in patients with psoriasis:a systematic review and meta-analysis. Lipids Health Dis, 15, 2016, 103.
27. Lo, J., Abbara, S., Rocha-Filho, J.A., Shturman, L., Wei, J., Grinspoon, S.K., Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters. AIDS 2 (2010), 2127–2130.
28. Long, B.D., Stojanovska, J., Brown, R.K.J., Attili, A.K., Jackson, E.A., Ognenovski, V., Increased epicardial fat volume is independently associated with the presence and severity of systemic sclerosis. Acad Radiol 24 (2017), 1473–1481.
29. Wernstedt Asterholm, I., Tao, C., Morley, T.S., et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab 20 (2014), 103–118.
30. Marchington, J.M., Pond, C.M., Site-specific properties of pericardial and epicardial adipose tissue: the effects of insulin and high-fat feeding on lipogenesis and the incorporation of fatty acids in vitro. Int J Obes 14 (1990), 1013–1022.
31. von Gise, A., Pu, W.T., Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. Circ Res 110 (2012), 1628–1645.
32. Suffee, N., Moore-Morris, T., Farahmand, P., et al. Atrial natriuretic peptide regulates adipose tissue accumulation in adult atria. Proc Natl Acad Sci U S A 114 (2017), E771–E780.
33. Thalmann, S., Meier, C.A., Local adipose tissue depots as cardiovascular risk factors. Cardiovasc Res 75 (2007), 690–701.
34. Mach, L., Bedanova, H., Soucek, M., et al. Impact of cardiopulmonary bypass surgery on cytokines in epicardial adipose tissue: comparison with subcutaneous fat. Perfusion 32 (2017), 279–284.
35. Hirata, Y., Kurobe, H., Akaike, M., et al. Enhanced inflammation in epicardial fat in patients with coronary artery disease. Int Heart J 52 (2011), 139–142.
36. Shibasaki, I., Nishikimi, T., Mochizuki, Y., et al. Greater expression of inflammatory cytokines, adrenomedullin, and natriuretic peptide receptor-C in epicardial adipose tissue in coronary artery disease. Regul Pept 165 (2010), 210–217.
37. Sinha, S.K., Thakur, R., Jha, M.J., et al. Epicardial adipose tissue thickness and its association with the presence and severity of coronary artery disease in clinical setting: a cross-sectional observational study. J Clin Med Res 8 (2016), 410–419.
38. Bo, X., Ma, L., Fan, J., et al. Epicardial fat volume is correlated with coronary lesion and its severity. Int J Clin Exp Med 8 (2015), 4328–4334.
39. Picard, F.A., Gueret, P., Laissy, J.P., et al. Epicardial adipose tissue thickness correlates with the presence and severity of angiographic coronary artery disease in stable patients with chest pain. PLoS One, 9, 2014, e110005.
40. Yerramasu, A., Dey, D., Venuraju, S., et al. Increased volume of epicardial fat is an independent risk factor for accelerated progression of sub-clinical coronary atherosclerosis. Atherosclerosis 220 (2012), 223–230.
41. Okada, K., Ohshima, S., Isobe, S., et al. Epicardial fat volume correlates with severity of coronary artery disease in nonobese patients. J Cardiovasc Med (Hagerstown) 15 (2014), 384–390.
42. Mach, L., Bedanova, H., Soucek, M., Karpisek, M., Nemec, P., Orban, M., Tobacco smoking and cytokine levels in human epicardial adipose tissue: Impact of smoking cessation. Atherosclerosis 255 (2016), 37–42.
43. McKenney-Drake, M.L., Rodenbeck, S.D., Bruning, R.S., et al. Epicardial adipose tissue removal potentiates outward remodeling and arrests coronary atherogenesis. Ann Thorac Surg 103 (2017), 1622–1630.
44. McKenney, M.L., Schultz, K.A., Boyd, J.H., et al. Epicardial adipose excision slows the progression of porcine coronary atherosclerosis. J Cardiothorac Surg, 9, 2014, 2.
45. Gorter, P.M., van Lindert, A.S., de Vos, A.M., et al. Quantification of epicardial and peri-coronary fat using cardiac computed tomography; reproducibility and relation with obesity and metabolic syndrome in patients suspected of coronary artery disease. Atherosclerosis 197 (2008), 896–903.
46. Abbara, S., Desai, J.C., Cury, R.C., Butler, J., Nieman, K., Reddy, V., Mapping epicardial fat with multi-detector computed tomography to facilitate percutaneous transepicardial arrhythmia ablation. Eur J Radiol 57 (2006), 417–422.
47. Wang, T.D., Lee, W.J., Shih, F.Y., et al. Association of epicardial adipose tissue with coronary atherosclerosis is region-specific and independent of conventional risk factors and intra-abdominal adiposity. Atherosclerosis 213 (2010), 279–287.
48. Verhagen, S.N., Rutten, A., Meijs, M.F., et al. Relationship between myocardial bridges and reduced coronary atherosclerosis in patients with angina pectoris. Int J Cardiol 167 (2013), 883–888.
49. Mahabadi, A.A., Reinsch, N., Lehmann, N., et al. Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: a segment analysis. Atherosclerosis 211 (2010), 195–199.
50. Sacks, H.S., Fain, J.N., Cheema, P., et al. Depot-specific overexpression of proinflammatory, redox, endothelial cell, and angiogenic genes in epicardial fat adjacent to severe stable coronary atherosclerosis. Metab Syndr Relat Disord 9 (2011), 433–439.
51. Verhagen, S.N., Visseren, F.L., Perivascular adipose tissue as a cause of atherosclerosis. Atherosclerosis 214 (2011), 3–10.
52. Aghamohammadzadeh, R., Unwin, R.D., Greenstein, A.S., Heagerty, A.M., Effects of obesity on perivascular adipose tissue vasorelaxant function: nitric oxide, inflammation and elevated systemic blood pressure. J Vasc Res 52 (2015), 299–305.
53. Lai, Y.H., Yun, C.H., Yang, F.S., et al. Epicardial adipose tissue relating to anthropometrics, metabolic derangements and fatty liver disease independently contributes to serum high-sensitivity C-reactive protein beyond body fat composition: a study validated with computed tomography. J Am Soc Echocardiogr 25 (2012), 234–241.
54. Nakanishi, K., Fukuda, S., Tanaka, A., et al. Epicardial adipose tissue accumulation is associated with renal dysfunction and coronary plaque morphology on multidetector computed tomography. Circ J 80 (2016), 196–201.
55. Cheng, K.H., Chu, C.S., Lee, K.T., et al. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes (Lond) 32 (2008), 268–274.
56. Kotulák, T., Drápalová, J., Kopecký, P., et al. Increased circulating and epicardial adipose tissue mRNA expression of fibroblast growth factor-21 after cardiac surgery: possible role in postoperative inflammatory response and insulin resistance. Physiol Res 60 (2011), 757–767.
57. Aydin, H., Toprak, A., Deyneli, O., et al. Epicardial fat tissue thickness correlates with endothelial dysfunction and other cardiovascular risk factors in patients with metabolic syndrome. Metab Syndr Relat Disord 8 (2010), 229–234.
58. Christensen, R.H., von Scholten, B.J., Hansen, C.S., et al. Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate. Eur J Prev Cardiol 24 (2017), 1517–1524.
59. Patel, V.B., Shah, S., Verma, S., Oudit, G.Y., Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. Heart Fail Rev 22 (2017), 889–902.
60. Baghdadi, L.R., Woodman, R.J., Shanahan, E.M., Mangoni, A.A., The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One, 10, 2015, e0117952.
61. Xiao, J., Chen, L.H., Tu, Y.T., Deng, X.H., Tao, J., Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol 23 (2009), 1311–1315.
62. Torres, T., Bettencourt, N., Mendonça, D., et al. Epicardial adipose tissue and coronary artery calcification in psoriasis patients. J Eur Acad Dermatol Venereol 29 (2015), 270–277.
63. Raggi, P., Zona, S., Scaglioni, R., et al. Epicardial adipose tissue and coronary artery calcium predict incident myocardial infarction and death in HIV-infected patients. J Cardiovasc Comput Tomogr 9 (2015), 553–558.
64. Temiz, A., Gökmen, F., Gazi, E., et al. Epicardial adipose tissue thickness, flow-mediated dilatation of the brachial artery, and carotid intima-media thickness: Associations in rheumatoid arthritis patients. Herz 40 Suppl 3 (2015), 217–224.
65. Iacobellis, G., Barbaro, G., The double role of epicardial adipose tissue as pro- and anti-inflammatory organ. Horm Metab Res 40 (2008), 442–445.
66. Iacobellis, G., Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol 11 (2015), 363–371.
67. Dueñas, A., Aranega, A.E., Franco, D., More than just a simple cardiac envelope; cellular contributions of the epicardium. Front Cell Dev Biol, 5, 2017, 44.
68. Löhn, M., Dubrovska, G., Lauterbach, B., Luft, F.C., Gollasch, M., Sharma, A.M., Periadventitial fat releases a vascular relaxing factor. FASEB J 16 (2002), 1057–1063.
69. Fitzgibbons, T.P., Kogan, S., Aouadi, M., Hendricks, G.M., Straubhaar, J., Czech, M.P., Similarity of mouse perivascular and brown adipose tissues and their resistance to diet-induced inflammation. Am J Physiol Heart Circ Physiol 301 (2011), H1425–H1437.
70. Antonopoulos, A.S., Margaritis, M., Verheule, S., et al. Mutual regulation of epicardial adipose tissue and myocardial redox State by PPAR-γ/adiponectin signalling. Circ Res 118 (2016), 842–855.
71. Teijeira-Fernandez, E., Eiras, S., Salgado Somoza, A., Gonzalez-Juanatey, J.R., Baseline epicardial adipose tissue adiponectin levels predict cardiovascular outcomes: a long-term follow-up study. Cytokine 60 (2012), 674–680.
72. Skrabal, C.A., Czaja, J., Honz, K., Emini, R., Hannekum, A., Friedl, R., Adiponectin–its potential to predict and prevent coronary artery disease. Thorac Cardiovasc Surg 59 (2011), 201–206.
73. Kourliouros, A., Karastergiou, K., Nowell, J., et al. Protective effect of epicardial adiponectin on atrial fibrillation following cardiac surgery. Eur J Cardiothorac Surg 39 (2011), 228–232.
74. Iacobellis, G., di Gioia, C.R., Cotesta, D., et al. Epicardial adipose tissue adiponectin expression is related to intracoronary adiponectin levels. Horm Metab Res 41 (2009), 227–231.
75. van Dam, A.D., Boon, M.R., Berbée, J.F.P., Rensen, P.C.N., van Harmelen, V., Targeting white, brown and perivascular adipose tissue in atherosclerosis development. Eur J Pharmacol 816 (2017), 82–92.
76. Gruzdeva, O.V., Akbasheva, O.E., Dyleva, Y.A., et al. Adipokine and cytokine profiles of epicardial and subcutaneous adipose tissue in patients with coronary heart disease. Bull Exp Biol Med 163 (2017), 608–611.
77. Patel, V.B., Basu, R., Oudit, G.Y., ACE2/Ang 1–7 axis: A critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity. Adipocyte 5 (2016), 306–311.
78. Company, J.M., Booth, F.W., Laughlin, M.H., et al. Epicardial fat gene expression after aerobic exercise training in pigs with coronary atherosclerosis: relationship to visceral and subcutaneous fat. J Appl Physiol (1985) 109 (2010), 1904–1912.
79. Bambace, C., Sepe, A., Zoico, E., et al. Inflammatory profile in subcutaneous and epicardial adipose tissue in men with and without diabetes. Heart Vessels 29 (2014), 42–48.
80. Naftali-Shani, N., Itzhaki-Alfia, A., Landa-Rouben, N., et al. The origin of human mesenchymal stromal cells dictates their reparative properties. J Am Heart Assoc, 2, 2013, e000253.
81. Naftali-Shani, N., Levin-Kotler, L.P., Palevski, D., et al. Left ventricular dysfunction switches mesenchymal stromal cells toward an inflammatory phenotype and impairs their re-parative properties via toll-like receptor-4. Circulation 135 (2017), 2271–2287.
82. Ruiz-Villalba, A., Simón, A.M., Pogontke, C., et al. Interacting resident epicardium-derived fibroblasts and recruited bone marrow cells form myocardial infarction scar. J Am Coll Cardiol 65 (2015), 2057–2066.
83. Song, D.K., Hong, Y.S., Lee, H., Oh, J.Y., Sung, Y.A., Kim, Y., Increased epicardial adipose tissue thickness in type 2 diabetes mellitus and obesity. Diabetes Metab J 39 (2015), 405–413.
84. Bentley-Lewis, R., Adler, G.K., Perlstein, T., et al. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 92 (2007), 4472–4475.
85. Huby, A.C., Antonova, G., Groenendyk, J., et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 132 (2015), 2134–2145.
86. Briones, A.M., Nguyen Dinh Cat, A., Callera, G.E., et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59 (2012), 1069–1078.
87. Iacobellis, G., Petramala, L., Marinelli, C., et al. Epicardial fat thickness and primary aldosteronism. Horm Metab Res 48 (2016), 238–241.
88. Wu, C., Zhang, H., Zhang, J., et al. Inflammation and fibrosis in perirenal adipose tissue of patients with aldosterone-producing adenoma. Endocrinology 159 (2018), 227–237.
89. Kraus, D., Jäger, J., Meier, B., Fasshauer, M., Klein, J., Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 37 (2005), 455–459.
90. Even, S.E., Dulak-Lis, M.G., Touyz, R.M., Nguyen Dinh Cat, A., Crosstalk between adipose tissue and blood vessels in cardiometabolic syndrome: implication of steroid hormone receptors (MR/GR). Horm Mol Biol Clin Investig 19 (2014), 89–101.
91. Qian, C., Schoemaker, R.G., van Gilst, W.H., Roks, A.J., The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function. Clin Sci (Lond) 116 (2009), 301–314.
92. Essick, E.E., Sam, F., Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor. Int J Hypertens, 2011, 2011, 346985.
93. Gutiérrez-Tenorio, J., Marín-Royo, G., Martínez-Martínez, E., et al. The role of oxidative stress in the crosstalk between leptin and mineralocorticoid receptor in the cardiac fibrosis associated with obesity. Sci Rep, 7, 2017, 16802.
94. Bender, S.B., DeMarco, V.G., Padilla, J., et al. Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension 65 (2015), 1082–1088.
95. Deswal, A., Richardson, P., Bozkurt, B., Mann, D.L., Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 17 (2011), 634–642.
96. Olivier, A., Pitt, B., Girerd, N., et al. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: Insight from the EMPHASIS-HF trial. Eur J Heart Fail 19 (2017), 1186–1197.
97. Patel, V.B., Mori, J., McLean, B.A., et al. ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity. Diabetes 65 (2016), 85–95.
98. Wu, C.K., Tsai, H.Y., Su, M.M., et al. Evolutional change in epicardial fat and its correlation with myocardial diffuse fibrosis in heart failure patients. J Clin Lipidol 11 (2017), 1421–1431.
99. Lin, Y.K., Chen, Y.C., Chang, S.L., et al. Heart failure epicardial fat increases atrial arrhythmogenesis. Int J Cardiol 167 (2013), 1979–1983.
100. Hatem, S.N., Sanders, P., Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res 102 (2014), 205–213.
101. Yorgun, H., Canpolat, U., Aytemir, K., et al. Association of epicardial and peri-atrial adiposity with the presence and severity of non-valvular atrial fibrillation. Int J Cardiovasc Imaging 31 (2015), 649–657.
102. Kusayama, T., Furusho, H., Kashiwagi, H., et al. Inflammation of left atrial epicardial adipose tissue is associated with paroxysmal atrial fibrillation. J Cardiol 68 (2016), 406–411.
103. Mahajan, R., Lau, D.H., Brooks, A.G., et al. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J Am Coll Cardiol 66 (2015), 1–11.
104. Venteclef, N., Guglielmi, V., Balse, E., et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J 36 (2015), 795–805.
105. Nagashima, K., Okumura, Y., Watanabe, I., et al. Does location of epicardial adipose tissue correspond to endocardial high dominant frequency or complex fractionated atrial electrogram sites during atrial fibrillation?. Circ Arrhythm Electrophysiol 5 (2012), 676–683.
106. Zghaib, T., Ipek, E.G., Zahid, S., et al. Association of left atrial epicardial adipose tissue with electrogram bipolar voltage and fractionation: electrophysiologic substrates for atrial fibrillation. Heart Rhythm 13 (2016), 2333–2339.
107. Nakanishi, K., Fukuda, S., Tanaka, A., Otsuka, K., Taguchi, H., Shimada, K., Relationships between periventricular epicardial adipose tissue accumulation, coronary microcirculation, and left ventricular diastolic dysfunction. Can J Cardiol 33 (2017), 1489–1497.
108. Natale, F., Tedesco, M.A., Mocerino, R., et al. Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives. Eur J Echocardiogr 10 (2009), 549–555.
109. Iacobellis, G., Leonetti, F., Singh, N., M Sharma, A., Relationship of epicardial adipose tissue with atrial dimensions and diastolic function in morbidly obese subjects. Int J Cardiol 115 (2007), 272–273.
110. Ozturk, C., Balta, S., Demirkol, S., Celik, T., Iyisoy, A., Epicardial adipose tissue thickness may be related diastolic dysfunction in obese adolescents. Eur Rev Med Pharmacol Sci, 18, 2014, 1109.
111. Hage, C., Michaëlsson, E., Linde, C., et al. Inflammatory biomarkers predict heart failure severity and prognosis in patients with heart failure with preserved ejection fraction: a holistic proteomic approach. Circ Cardiovasc Genet, 10, 2017, e001633.
112. Chan, M.M., Santhanakrishnan, R., Chong, J.P., et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 18 (2016), 81–88.
113. Glezeva, N., Voon, V., Watson, C., et al. Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: evidence of M2 macrophage activation in disease pathogenesis. J Card Fail 21 (2015), 167–177.
114. Lam, C.S., Lyass, A., Kraigher-Krainer, E., et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 124 (2011), 24–30.
115. Mavrogeni, S., Karabela, G., Stavropoulos, E., et al. Imaging patterns of heart failure in rheumatoid arthritis evaluated by cardiovascular magnetic resonance. Int J Cardiol 168 (2013), 4333–4335.
116. Holloway, C.J., Ntusi, N., Suttie, J., et al. Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation 128 (2013), 814–822.
117. Liang, K.P., Myasoedova, E., Crowson, C.S., et al. Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann Rheum Dis 69 (2010), 1665–1670.
118. Davis, J.M. 3rd, Lin, G., Oh, J.K., et al. Five-year changes in cardiac structure and function in patients with rheumatoid arthritis compared with the general population. Int J Cardiol 240 (2017), 379–385.
119. Fontes-Carvalho, R., Mancio, J., Marcos, A., et al. HIV patients have impaired diastolic function that is not aggravated by anti-retroviral treatment. Cardiovasc Drugs Ther 29 (2015), 31–39.
120. Ozden, H.K., Polat, M., Ozturk, S., Bugdayci, G., Assessment of subclinical cardiac damage in chronic plaque psoriasis patients: a case control study. Arch Med Sci Atheroscler Dis 1 (2016), e126–e132.
121. Atas, H., Kepez, A., Bozbay, M., et al. Assessment of left atrial volume and function in patients with psoriasis by using real time three-dimensional echocardiography. Wien Klin Wochenschr 127 (2015), 858–863.
122. Arosio, E., De Marchi, S., Rigoni, A., Prior, M., Delva, P., Lechi, A., Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis. J Hypertens 25 (2007), 1273–1278.
123. Franssen, C., Chen, S., Unger, A., et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. J Am Coll Cardiol HF 4 (2016), 312–324.
124. Davis, J.M. 3rd, Roger, V.L., Crowson, C.S., Kremers, H.M., Therneau, T.M., Gabriel, S.E., The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum 58 (2008), 2603–2611.
125. Mantel, Ä., Holmqvist, M., Andersson, D.C., Lund, L.H., Askling, J., Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure. J Am Coll Cardiol 69 (2017), 1275–1285.
126. Steverson, A.B., Pawlowski, A.E., Schneider, D., et al. Clinical characteristics of HIV-infected patients with adjudicated heart failure. Eur J Prev Cardiol 24 (2017), 1746–1758.
127. Freiberg, M.S., Chang, C.H., Skanderson, M., et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the Veterans Aging Cohort Study. JAMA Cardiol 2 (2017), 536–546.
128. Khalid, U., Ahlehoff, O., Gislason, G.H., et al. Psoriasis and risk of heart failure: a nationwide cohort study. Eur J Heart Fail 16 (2014), 743–748.
129. Pedone, C., Roshanravan, B., Scarlata, S., Patel, K.V., Ferrucci, L., Incalzi, R.A., Longitudinal association between serum leptin concentration and glomerular filtration rate in humans. PLoS One, 10, 2015, e0117828.
130. Wolf, G., Ziyadeh, F.N., Leptin and renal fibrosis. Contrib Nephrol 151 (2006), 175–183.
131. Ozturk, M.T., Ebinç, F.A., Okyay, G.U., Kutlugün, A.A., Epicardial adiposity is associated with microalbuminuria in patients with essential hypertension. Acta Cardiol Sin 33 (2017), 74–80.
132. Kiraz, K., Gökdeniz, T., Kalaycıoglu, E., et al. Epicardial fat thickness is associated with severity of disease in patients with chronic obstructive pulmonary disease. Eur Rev Med Pharmacol Sci 20 (2016), 4508–4515.
133. Akıl, E., Akıl, M.A., Varol, S., et al. Echocardiographic epicardial fat thickness and neutrophil to lymphocyte ratio are novel inflammatory predictors of cerebral ischemic stroke. J Stroke Cerebrovasc Dis 23 (2014), 2328–2334.
134. Mentz, R.J., Kelly, J.P., von Lueder, T.G., et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 64 (2014), 2281–2293.
135. Gomberg-Maitland, M., Shah, S.J., Guazzi, M., Inflammation in heart failure with preserved ejection fraction: time to put out the fire. J Am Coll Cardiol HF 4 (2016), 325–328.
136. Cherian, S., Lopaschuk, G.D., Carvalho, E., Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease. Am J Physiol Endocrinol Metab 303 (2012), E937–E949.
137. Gaborit, B., Jacquier, A., Kober, F., et al. Effects of bariatric surgery on cardiac ectopic fat: lesser decrease in epicardial fat compared to visceral fat loss and no change in myocardial triglyceride content. J Am Coll Cardiol 60 (2012), 1381–1389.
138. Illán-Gómez, F., Gonzálvez-Ortega, M., Orea-Soler, I., et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg 22 (2012), 950–955.
139. Chang, H.X., Zhao, X.J., Zhu, Q.L., Hou, Q., Li, Y., Removal of epicardial adipose tissue after myocardial infarction improves cardiac function. Herz, 2017 Apr 4 [E-pub ahead of print].
140. Smail, H., Baciu, A., Dacher, J.N., Litzler, P.Y., Surgical resection of circumferential epicardial adipose tissue hypertrophy: case report and systematic review of the literature. J Thorac Cardiovasc Surg 151 (2016), e27–e30.
141. Soucek, F., Covassin, N., Singh, P., et al. Effects of atorvastatin (80 mg) therapy on quantity of epicardial adipose tissue in patients undergoing pulmonary vein isolation for atrial fibrillation. Am J Cardiol 116 (2015), 1443–1446.
142. Cho, K.I., Kim, B.J., Cha, T.J., Heo, J.H., Kim, H.S., Lee, J.W., Impact of duration and dosage of statin treatment and epicardial fat thickness on the recurrence of atrial fibrillation after electrical cardioversion. Heart Vessels 30 (2015), 490–497.
143. Yamada, Y., Takeuchi, S., Yoneda, M., et al. Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome. Int J Cardiol 240 (2017), 332–338.
144. Alexopoulos, N., Melek, B.H., Arepalli, C.D., et al. Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning). J Am Coll Cardiol 61 (2013), 1956–1961.
145. Abe, M., Matsuda, M., Kobayashi, H., et al. Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages. Arterioscler Thromb Vasc Biol 28 (2008), 871–877.
146. Busnelli, M., Manzini, S., Froio, A., et al. Diet induced mild hypercholesterolemia in pigs: local and systemic inflammation, effects on vascular injury - rescue by high-dose statin treatment. PLoS One, 8, 2013, e80588.
147. Horiuchi, Y., Hirayama, S., Soda, S., et al. Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels. J Atheroscler Thromb 17 (2010), 722–729.
148. Bonnet, J., McPherson, R., Tedgui, A., et al. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther 30 (2008), 2298–2313.
149. González, N., Moreno-Villegas, Z., González-Bris, A., Egido, J., Lorenzo Ó. Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes. Cardiovasc Diabetol, 16, 2017, 44.
150. Wu, C.K., Yeh, C.F., Chiang, J.Y., et al. Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients-the ALEVENT clinical trial. J Clin Lipidol 11 (2017), 657–666.
151. Beck, A.L., Otto, M.E., D'Avila, L.B., Netto, F.M., Armendaris, M.K., Sposito, A.C., Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals. Atherosclerosis 222 (2012), 444–448.
152. Li, J.J., Zheng, X., Li, J., Statins may be beneficial for patients with slow coronary flow syndrome due to its anti-inflammatory property. Med Hypotheses 69 (2007), 333–337.
153. Choi, S.Y., Park, J.S., Roh, M.S., Kim, C.R., Kim, M.H., Serebruany, V., Inhibition of angiotensin II-Induced cardiac fibrosis by atorvastatin in adiponectin knockout mice. Lipids 52 (2017), 415–422.
154. Chen, M., Li, H., Wang, G., Shen, X., Zhao, S., Su, W., Atorvastatin prevents advanced glycation end products (AGEs)-induced cardiac fibrosis via activating peroxisome proliferator-activated receptor gamma (PPAR-γ). Metabolism 65 (2016), 441–453.
155. Akahori, H., Tsujino, T., Naito, Y., et al. Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats. J Hypertens 32 (2014), 1534–1541.
156. Yamamoto, C., Fukuda, N., Jumabay, M., et al. Protective effects of statin on cardiac fibrosis and apoptosis in adrenomedullin-knockout mice treated with angiotensin II and high salt loading. Hypertens Res 34 (2011), 348–353.
157. Yagi, S., Aihara, K., Ikeda, Y., et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res 102 (2008), 68–76.
158. Loch, D., Levick, S., Hoey, A., Brown, L., Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol 47 (2006), 396–404.
159. Preiss, D., Campbell, R.T., Murray, H.M., et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J 36 (2015), 1536–1546.
160. Fukuta, H., Goto, T., Wakami, K., Ohte, N., The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses. Int J Cardiol 214 (2016), 301–306.
161. Liu, G., Zheng, X.X., Xu, Y.L., Ru, J., Hui, R.T., Huang, X.H., Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol 113 (2014), 1198–1204.
162. Nochioka, K., Sakata, Y., Miyata, S., et al. Prognostic impact of statin use in patients with heart failure and preserved ejection fraction. Circ J 79 (2015), 574–582.
163. Ashton, E., Windebank, E., Skiba, M., et al. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol 146 (2011), 404–407.
164. Kjekshus, J., Apetrei, E., Barrios, V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007), 2248–2261.
165. Altara, R., Giordano, M., Nordén, E.S., et al. Targeting obesity and diabetes to treat heart failure with preserved ejection fraction. Front Endocrinol (Lausanne), 8, 2017, 160.
166. Udell, J.A., Cavender, M.A., Bhatt, D.L., Chatterjee, S., Farkouh, M.E., Scirica, B.M., Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 3 (2015), 356–366.
167. Cignarelli, A., Giorgino, F., Vettor, R., Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis. Arch Physiol Biochem 119 (2013), 139–150.
168. Manhiani, M.M., Cormican, M.T., Brands, M.W., Chronic sodium-retaining action of insulin in diabetic dogs. Am J Physiol Renal Physiol 300 (2011), F957–F965.
169. Tiwari, S., Riazi, S., Ecelbarger, C.A., Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol 293 (2007), F974–F984.
170. Nichols, G.A., Koro, C.E., Gullion, C.M., Ephross, S.A., Brown, J.B., The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 21 (2005), 51–57.
171. Shi, H., Moustaid-Moussa, N., Wilkison, W.O., Zemel, M.B., Role of the sulfonylurea receptor in regulating human adipocyte metabolism. FASEB J 13 (1999), 1833–1838.
172. Skowroński, R., Madrala, A., Angielski, S., Sulphonylureas-induced increase in insulin binding and glucose metabolism by isolated rat adipocytes. Horm Metab Res 20 (1988), 77–81.
173. Miller, R.E., Bhandari, B., Glyburide action in cultured 3T3-L1 adipocytes. Biochem Int 13 (1986), 313–319.
174. Sivitz, W.I., Wayson, S.M., Bayless, M.L., et al. Leptin and body fat in type 2 diabetes and monodrug therapy. J Clin Endocrinol Metab 88 (2003), 1543–1553.
175. Haffner, S.M., Hanefeld, M., Fischer, S., Fuçker, K., Leonhardt, W., Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care 20 (1997), 1430–1434.
176. Packer, M., Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial. Eur J Heart Fail 20 (2018), 49–51.
177. Grosso, A.F., de Oliveira, S.F., Higuchi Mde, L., Favarato, D., Dallan, L.A., da Luz, P.L., Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome. Diabetol Metab Syndr, 6, 2014, 47.
178. Sacks, H.S., Fain, J.N., Cheema, P., et al. Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. Diabetes Care 34 (2011), 730–733.
179. Distel, E., Penot, G., Cadoudal, T., Balguy, I., Durant, S., Benelli, C., Early induction of a brown-like phenotype by rosiglitazone in the epicardial adipose tissue of fatty Zucker rats. Biochimie 94 (2012), 1660–1667.
180. Dormandy, J.A., Charbonnel, B., Eckland, D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
181. Kernan, W.N., Viscoli, C.M., Furie, K.L., et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
182. Panchapakesan, U., Pollock, C., Saad, S., Importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake. Nephrology (Carlton) 14 (2009), 298–301.
183. Lincoff, A.M., Wolski, K., Nicholls, S.J., Nissen, S.E., Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007), 1180–1188.
184. Cantini, G., Di Franco, A., Samavat, J., Forti, G., Mannucci, E., Luconi, M., Effect of liraglutide on proliferation and differentiation of human adipose stem cells. Mol Cell Endocrinol 402 (2015), 43–50.
185. Suzuki, M., Takeda, M., Kito, A., et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes, 4, 2014, e125.
186. Iacobellis, G., Mohseni, M., Bianco, S.D., Banga, P.K., Liraglutide causes large and rapid epicardial fat reduction. Obesity (Silver Spring) 25 (2017), 311–316.
187. Dutour, A., Abdesselam, I., Ancel, P., et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab 18 (2016), 882–891.
188. Pastel, E., McCulloch, L.J., Ward, R., et al. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction. Clin Sci (Lond) 131 (2017), 343–353.
189. Al-Barazanji, K.A., Arch, J.R., Buckingham, R.E., Tadayyon, M., Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes Res 8 (2000), 317–323.
190. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
191. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
192. Lima-Martínez, M.M., Paoli, M., Rodney, M., et al. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. Endocrine 51 (2016), 448–455.
193. Kim, D., Kim, J., Yoon, J.H., et al. CXCL12 secreted from adipose tissue recruits macrophages and induces insulin resistance in mice. Diabetologia 57 (2014), 1456–1465.
194. Packer, M., Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. Cardiovasc Diabetol, 17, 2018, 9.
195. Peng, H., Zhang, H., Zhu, H., Blocking CXCR7-mediated adipose tissue macrophages chemotaxis attenuates insulin resistance and inflammation in obesity. Biochem Biophys Res Commun 479 (2016), 649–655.
196. Mulvihill, E.E., Varin, E.M., Ussher, J.R., et al. Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice. Diabetes 65 (2016), 742–754.
197. Jackson, E.K., Zhang, Y., Gillespie, D.D., Zhu, X., Cheng, D., Jackson, T.C., SDF-1α (stromal cell-derived factor 1α) induces cardiac fibroblasts, renal microvascular smooth muscle cells, and glomerular mesangial cells to proliferate, cause hypertrophy, and produce collagen. J Am Heart Assoc, 6, 2017, e007253.
198. Chu, P.Y., Zatta, A., Kiriazis, H., et al. CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circ Heart Fail 4 (2011), 651–658.
199. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. April 5, 2016. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm486096.htm Accessed December 27, 2017.
200. McMurray, J.J.V., Ponikowski, P., Bolli, G.B., et al. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. J Am Coll Cardiol HF 6 (2018), 8–17.
201. Jonker, J.T., Lamb, H.J., van der Meer, R.W., et al. Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95 (2010), 456–460.
202. Bouchi, R., Terashima, M., Sasahara, Y., et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol, 16, 2017, 32.
203. Fukuda, T., Bouchi, R., Terashima, M., et al. Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study. Diabetes Ther 8 (2017), 851–861.
204. Cameron, A.R., Morrison, V.L., Levin, D., et al. Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res 119 (2016), 652–665.
205. Xiao, H., Ma, X., Feng, W., et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res 87 (2010), 504–513.
206. Andersson, C., Søgaard, P., Hoffmann, S., et al. Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes. Eur J Endocrinol 163 (2010), 593–599.
207. Hammoudi, N., Jeong, D., Singh, R., et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther 31 (2017), 233–246.
208. Habibi, J., Aroor, A.R., Sowers, J.R., et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol, 16, 2017, 9.
209. Kusaka, H., Koibuchi, N., Hasegawa, Y., Ogawa, H., Kim-Mitsuyama, S., Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol, 15, 2016, 157.
210. Lee, T.M., Chang, N.C., Lin, S.Z., Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 104 (2017), 298–310.
211. Cittadini, A., Napoli, R., Monti, M.G., et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 61 (2012), 944–953.
212. Joubert, M., Jagu, B., Montaigne, D., et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes 66 (2017), 1030–1040.
213. Eurich, D.T., Weir, D.L., Majumdar, S.R., et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 6 (2013), 395–402.
214. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular out-comes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
215. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
216. Guo, C., Ricchiuti, V., Lian, B.Q., et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 117 (2008), 2253–2261.
217. Wada, T., Ishikawa, A., Watanabe, E., et al. Eplerenone prevented obesity-induced inflammasome activation and glucose intolerance. J Endocrinol 235 (2017), 179–191.
218. Anand, I.S., Rector, T.S., Cleland, J.G., et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4 (2011), 569–577.
219. Anand, I.S., Claggett, B., Liu, J., et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. J Am Coll Cardiol HF 5 (2017), 241–252.
220. Moro, C., Klimcakova, E., Lolmède, K., et al. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 50 (2007), 1038–1047.
221. Bae, C.R., Hino, J., Hosoda, H., et al. Overexpression of C-type natriuretic peptide in endothelial cells protects against insulin resistance and inflammation during diet-induced obesity. Sci Rep, 7, 2017, 9807.
222. Tamura, N., Ogawa, Y., Chusho, H., et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 97 (2000), 4239–4244.
223. Lanfear, D.E., Chow, S., Padhukasahasram, B., et al. Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide. J Card Fail 20 (2014), 662–668.
224. Standeven, K.F., Hess, K., Carter, A.M., et al. Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond) 35 (2011), 1031–1040.
225. Bordicchia, M., Ceresiani, M., Pavani, M., et al. Insulin/glucose induces natriuretic peptide clearance receptor in human adipocytes: a metabolic link with the cardiac natriuretic pathway. Am J Physiol Regul Integr Comp Physiol 311 (2016), R104–R114.
226. Solomon, S.D., Zile, M., Pieske, B., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380 (2012), 1387–1395.
227. Wu, W., Shi, F., Liu, D., et al. Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance. Sci Signal, 10, 2017 eaam6870.
228. Mazurek, T., Zhang, L., Zalewski, A., et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108 (2003), 2460–2466.